ClinicalTrials.gg
CompletedNCT00138762Updated Feb 17, 2012

A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol

A Phase 3 interventional study of torcetrapib/atorvastatin and atorvastatin in Hyperlipidemia, sponsored by Pfizer. Completed at 154 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-17.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 37 studies testing atorvastatin in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. Atorvastatin · Hyperlipidemias.

Enrollment
Largest of 37
3,800 · median 99
Started
2004
with 2 others
Phase 3
10 of 37
none open now
Registered
6th of 37
by date
Lead sponsor
5 of 37
Pfizer

Among the 37 studies testing atorvastatin in Hyperlipidemias, this one has the largest enrollment, is one of 3 that started in 2004, is one of 10 in phase 3, and was the 6th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 108 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 37 studies testing atorvastatin in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 37 studies testing atorvastatin in Hyperlipidemias as a file.
02

Study summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.

Read the detailed description

For additional information please call: 1-800-718-1021

03

Conditions studied

  • Hyperlipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects with elevated cholesterol

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Intolerance to statin therapy resulting in withdrawal
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
3,800 participants

Interventions

06

What researchers measure

Primary outcomes

  1. LDL and HDL levels

Secondary outcomes

  1. other lipid parameters

07

Study locations

154 sites
  • Pfizer Investigational Site
    Mobile, Alabama, United States
  • Pfizer Investigational Site
    Mesa, Arizona, United States
  • Pfizer Investigational Site
    Oro Valley, Arizona, United States
  • Pfizer Investigational Site
    Phoenix, Arizona, United States
  • Pfizer Investigational Site
    Sun City, Arizona, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas, United States
  • Pfizer Investigational Site
    Anaheim, California, United States
  • Pfizer Investigational Site
    Carmichael, California, United States
  • Pfizer Investigational Site
    Concord, California, United States
  • Pfizer Investigational Site
    Greenbrae, California, United States
  • Pfizer Investigational Site
    Los Angeles, California, United States
  • Pfizer Investigational Site
    Mission Viejo, California, United States
  • Pfizer Investigational Site
    Sacramento, California, United States
  • Pfizer Investigational Site
    Santa Ana, California, United States
  • Pfizer Investigational Site
    Stockton, California, United States
  • Pfizer Investigational Site
    Thouasand Oaks, California, United States
  • Pfizer Investigational Site
    Tustin, California, United States
  • Pfizer Investigational Site
    Upland, California, United States
  • Pfizer Investigational Site
    Walnut Creek, California, United States
  • Pfizer Investigational Site
    Westlake Village, California, United States
  • Pfizer Investigational Site
    Boulder, Colorado, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut, United States
  • Pfizer Investigational Site
    Newark, Delaware, United States
  • Pfizer Investigational Site
    Coral Gables, Florida, United States
  • Pfizer Investigational Site
    Ft. Pierce, Florida, United States
  • Pfizer Investigational Site
    Jacksonville, Florida, United States
  • Pfizer Investigational Site
    Jupiter, Florida, United States
  • Pfizer Investigational Site
    Lake Worth, Florida, United States
  • Pfizer Investigational Site
    Melbourne, Florida, United States
  • Pfizer Investigational Site
    Palm Bay, Florida, United States
  • Pfizer Investigational Site
    Sebastian, Florida, United States
  • Pfizer Investigational Site
    Stuart, Florida, United States
  • Pfizer Investigational Site
    Vero Beach, Florida, United States
  • Pfizer Investigational Site
    Wellington, Florida, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida, United States
  • Pfizer Investigational Site
    Chicago, Illinois, United States
  • Pfizer Investigational Site
    Creve Coevr, Illinois, United States
  • Pfizer Investigational Site
    Peoria, Illinois, United States
  • Pfizer Investigational Site
    Rockford, Illinois, United States
  • Pfizer Investigational Site
    Iowa City, Iowa, United States
  • Pfizer Investigational Site
    Kansas City, Kansas, United States
  • Pfizer Investigational Site
    Overland Park, Kansas, United States
  • Pfizer Investigational Site
    Wichita, Kansas, United States
  • Pfizer Investigational Site
    Erlanger, Kentucky, United States
  • Pfizer Investigational Site
    Louisville, Kentucky, United States
  • Pfizer Investigational Site
    Covington, Louisiana, United States
  • Pfizer Investigational Site
    Slidell, Louisiana, United States
  • Pfizer Investigational Site
    Scarborough, Maine, United States
  • Pfizer Investigational Site
    Baltimore, Maryland, United States
  • Pfizer Investigational Site
    Bethesda, Maryland, United States
  • Pfizer Investigational Site
    Elkton, Maryland, United States
  • Pfizer Investigational Site
    Jackson, Mississippi, United States
  • Pfizer Investigational Site
    Jefferson City, Missouri, United States
  • Pfizer Investigational Site
    Kansas City, Missouri, United States
  • Pfizer Investigational Site
    Billings, Montana, United States
  • Pfizer Investigational Site
    Lincoln, Nebraska, United States
  • Pfizer Investigational Site
    Omaha, Nebraska, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada, United States
  • Pfizer Investigational Site
    Endwell, New York, United States
  • Pfizer Investigational Site
    Lake Success, New York, United States
  • Pfizer Investigational Site
    Rochester, New York, United States
  • Pfizer Investigational Site
    Williamsville, New York, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina, United States
  • Pfizer Investigational Site
    Concord, North Carolina, United States
  • Pfizer Investigational Site
    Fayetteville, North Carolina, United States
  • Pfizer Investigational Site
    Monroe, North Carolina, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio, United States
  • Pfizer Investigational Site
    Elyria, Ohio, United States
  • Pfizer Investigational Site
    Olmsted Township, Ohio, United States
  • Pfizer Investigational Site
    Westlake, Ohio, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma, United States
  • Pfizer Investigational Site
    Beaverton, Oregon, United States
  • Pfizer Investigational Site
    Hillsboro, Oregon, United States
  • Pfizer Investigational Site
    Portland, Oregon, United States
  • Pfizer Investigational Site
    Warwick, Rhode Island, United States
  • Pfizer Investigational Site
    Greer, South Carolina, United States
  • Pfizer Investigational Site
    Spartanburg, South Carolina, United States
  • Pfizer Investigational Site
    Kingsport, Tennessee, United States
  • Pfizer Investigational Site
    Nashville, Tennessee, United States
  • Pfizer Investigational Site
    Austin, Texas, United States
  • Pfizer Investigational Site
    Beaumont, Texas, United States
  • Pfizer Investigational Site
    Bryan, Texas, United States
  • Pfizer Investigational Site
    Dallas, Texas, United States
  • Pfizer Investigational Site
    Houston, Texas, United States
  • Pfizer Investigational Site
    San Antonio, Texas, United States
  • Pfizer Investigational Site
    The Colony, Texas, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah, United States
  • Pfizer Investigational Site
    Newport News, Virginia, United States
  • Pfizer Investigational Site
    Norfolk, Virginia, United States
  • Pfizer Investigational Site
    Richmond, Virginia, United States
  • Pfizer Investigational Site
    Renton, Washington, United States
  • Pfizer Investigational Site
    Yakima, Washington, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin, United States
  • Pfizer Investigational Site
    Oregon, Wisconsin, United States
  • Pfizer Investigational Site
    Bruxelles, Belgium
  • Pfizer Investigational Site
    Dottignies, Belgium
  • Pfizer Investigational Site
    Ham, Belgium
  • Pfizer Investigational Site
    Hasselt, Belgium

Showing the first 100 of 154 sites across 8 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2005
First posted
Aug 30, 2005
Start
Jul 2004
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Results delay requested
Feb 15, 2012
Last update
Feb 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00138762
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 30, 2005
Start date
Jul 2004
Primary completion
Aug 2006
Completion
Aug 2006
Last update
Feb 17, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torcetrapib · Atorvastatin

Start the discussion